Enjoy complimentary customisation on priority with our Enterprise License!
The narcolepsy drugs market size is forecast to increase by USD 1.81 billion, at a CAGR of 10.03% between 2023 and 2028. Market growth is influenced by several significant factors. Firstly, the rising number of product launches and clinical trials reflects ongoing efforts to innovate and improve treatment options for narcolepsy. These initiatives aim to introduce new therapies that address unmet medical needs and enhance patient outcomes. Secondly, there is a noticeable increase in reported cases of narcolepsy among adults, highlighting the growing awareness and diagnosis of the condition. Thirdly, the escalating number of studies dedicated to understanding the causes and developing effective treatments for narcolepsy underscores a broader commitment to advancing scientific knowledge in this area. Together, these factors drive the evolution of the narcolepsy treatment market, fostering advancements in medical research, therapeutic options, and patient care strategies to better support individuals affected by narcolepsy.
For More Highlights About this Report, Request Free Sample
Narcolepsy is a chronic sleep disorder characterized by daytime extreme sleepiness, sleep attacks, and sudden loss of muscle tone, known as cataplexy. The prevalence of narcolepsy is increasing due to the aging population and rising stress levels. According to the National Sleep Foundation, an estimated 1 in 2,000 American adults have narcolepsy. The disorder can significantly impact an individual's quality of life, leading to healthcare expenditure and a need for effective treatments. Narcolepsy drugs are essential in managing the symptoms of the disorder. These medications include psychostimulants, such as modafinil and methylphenidate, which help increase wakefulness. Sodium oxybate, a sodium salt of gamma-hydroxybutyric acid, is another commonly used drug for the treatment of narcolepsy and cataplexy.
Further, the reimbursement environment for narcolepsy drugs varies, depending on the specific medication and country. Factors such as medical infrastructure, central hypersomnia, circadian delay, and lifestyle changes can influence the use and effectiveness of these drugs. Alcohol and tobacco use can also worsen the symptoms of narcolepsy and impact the response to medications. The market is expected to grow due to the increasing prevalence of the disorder and the need for effective treatments. However, the high cost of these medications and the complex reimbursement environment may limit their widespread use. The brain's sleep-wake cycles play a crucial role in the development and management of narcolepsy, and ongoing research in this area may lead to new and more effective treatments in the future.
Rising product launches and clinical trials is notably driving market growth. The market for narcolepsy drugs has experienced significant growth due to the rising number of diagnosed cases. In response to this demand, pharmaceutical companies have introduced new treatments to provide medical care for those affected. For instance, in 2020, Jazz Pharmaceuticals received FDA approval for Xywav, an oral solution for cataplexy or excessive daytime sleepiness in narcolepsy patients aged seven and above. Similarly, Avadel Pharmaceuticals's new drug application (NDA) for FT218, which treats excessive daytime sleepiness and cataplexy in adults with narcolepsy, was accepted by the FDA in 2021. A recent phase 3 study conducted at Stanford University demonstrated that an extended-release version of sodium oxybate effectively reduces daytime sleepiness and improves muscle weakness in patients with narcolepsy.
Further, with the increasing prevalence of this orphan disease, particularly among the overweight populace, and the pressure to stay alert in various professions such as hospital workers and public transport personnel, the need for effective narcolepsy treatments continues to grow. During the treatment process, it is crucial for patients to ensure their safety by wearing personal protective equipment like face masks, gloves, eye protection, and appropriate clothing to prevent respiratory distress syndrome and other complications. The circadian system, which is affected in narcolepsy, is sensitive to the light-dark cycle, making it essential to maintain a consistent routine and take medications as prescribed. Thus, such factors are driving the growth of the market during the forecast period.
Advancement in narcolepsy treatment is the key trend in the market. Narcolepsy, an orphan disease characterized by uncontrollable sleep attacks and other disruptive sleep-related symptoms, necessitates personalized medical care due to its variable manifestations in different patients. Treatment for this condition involves a combination of medication and lifestyle modifications to enhance sleep hygiene. Stimulants like Provigil (modafinil) and Nuvigil (armodafinil) are commonly prescribed to manage excessive daytime sleepiness and improve wakefulness. Xyrem (sodium oxybate), another medication, targets cataplexy attacks and enhances the sleep cycle, thereby reducing sleep paralysis and hallucinations.
Moreover, effexor (venlafaxine) is another prescription drug that helps regulate brain chemicals, specifically Orexin and Hypocretin, which are implicated in narcolepsy. In addition to medication, precautions such as wearing personal protective equipment like face masks, gloves, eye protection, and appropriate clothing during public transport and hospital work can help prevent respiratory distress syndrome and other complications. The circadian system, influenced by the light-dark cycle, plays a crucial role in regulating sleep patterns. An overweight populace and peer pressure can exacerbate symptoms, making it essential to prioritize good sleep hygiene and regular medical care. Thus, such trends will shape the growth of the market during the forecast period.
Lack of awareness is the major challenge that affects the growth of the market. Narcolepsy, an orphan disease characterized by excessive daytime sleepiness and sudden attacks of sleep, remains underdiagnosed due to limited public awareness. Misinterpretation of symptoms as laziness or a character flaw often leads to inappropriate prescriptions of antiepileptics and psychotropics, which can adversely affect the health of affected individuals, particularly children and adolescents. A survey conducted in the US by Jazz Pharmaceuticals revealed that only half of Americans understand the health implications of narcolepsy. Physicians face challenges in recognizing and diagnosing the condition, with only 9% of primary care physicians and 42% of sleep specialists expressing comfort in diagnosing it. The circadian system, regulated by the light-dark cycle, plays a crucial role in sleep-wake cycles. Narcolepsy is linked to a deficiency in the brain chemical orexin, also known as hypocretin, which affects the brain's ability to regulate sleep. Individuals with narcolepsy may experience cataplexy, a sudden loss of muscle tone, and sleep paralysis, a temporary inability to move or speak during the transition between sleep and wakefulness. The condition can also increase the risk of respiratory distress syndrome during anesthesia and surgery.
In addition, individuals with narcolepsy may face stigma and peer pressure, leading to a reluctance to seek medical care. To mitigate the risk of infection during medical care, it is essential to wear personal protective equipment, including face masks, gloves, eye protection, and clothing. Hospital workers and public transport users are at a higher risk of contracting infections. Brain tumors are a rare comorbidity in narcolepsy. The overweight populace is also at a higher risk of developing the condition. Stimulants are often prescribed to manage excessive daytime sleepiness, but their long-term use can have side effects. Therefore, early diagnosis and appropriate treatment are crucial to improve the quality of life for individuals with narcolepsy. Hence, the above factors will impede the growth of the market during the forecast period
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Alkermes Public Ltd. Co. - The company offers narcolepsy drugs such as ALKS 2680 tablets.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The narcolepsy with cataplexy segment is estimated to witness significant growth during the forecast period. Narcolepsy, a chronic sleep disorder characterized by daytime extreme sleepiness and sudden, uncontrollable sleep attacks, affects an estimated 200,000 American adults. With an aging population and increasing stress levels, the prevalence of narcoleptic diseases is expected to rise. The healthcare expenditure on narcolepsy treatments is projected to grow as a result. Medical infrastructure, including hospitals and diagnostic centers, plays a crucial role in the diagnosis and management of this condition. Central hypersomnia, circadian delay, cataplexy, and sleepiness are common symptoms of narcolepsy.
Get a glance at the market share of various regions Download the PDF Sample
The narcolepsy with cataplexy was the largest and was valued at USD 1.31 billion in 2018. Narcolepsy drugs, such as psychostimulants, tricyclic antidepressants, sodium oxybate, modafinil, antiepileptics, and psychiatric medications, are used to manage the symptoms. The reimbursement environment for these medications varies, which can impact their accessibility. Obesity rates, addictive substances like alcohol and tobacco, and sleep interruptions exacerbate the condition. Lifestyle changes and medications are essential for managing the chronic problem. Drug development is ongoing to improve the efficacy and safety of existing treatments and to discover new ones. Polysomnography, a diagnostic tool, is used to identify sleep disorders, including narcolepsy.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 51% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.Narcolepsy, a chronic sleep disorder characterized by daytime extreme sleepiness and sudden, uncontrollable sleep attacks, is experiencing increased prevalence due to the aging population and rising stress levels. The global market for narcolepsy drugs is anticipated to grow significantly as a result of the increasing healthcare expenditure and advancements in medical infrastructure. Central hypersomnia, a type of narcoleptic disease, and circadian delay are major conditions driving the demand for effective narcolepsy treatments. Narcolepsy disorder is diagnosed through polysomnography and other diagnostic tests in hospitals and diagnostic centers.
In addition, the reimbursement environment for narcolepsy drugs varies across regions, impacting their availability and affordability. Psychostimulants, tricyclic antidepressants, sodium oxybate, and medications like Modafinil, antiepepileptics, and psychiatric medications are commonly used to manage symptoms. Obesity rates, addictive substances such as alcohol and tobacco, and sleep interruptions are significant factors contributing to the chronic nature of this disorder. The development of new medications and lifestyle changes are crucial in managing narcolepsy and mitigating its impact on individuals' quality of life.
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments.
You may also interested in below market reports:
Narcolepsy is a chronic sleep disorder characterized by excessive daytime sleepiness, sudden and uncontrollable sleep attacks, and cataplexy, a sudden loss of muscle tone. The global market for Narcolepsy drugs is witnessing significant growth due to several factors, including the aging population, increasing stress levels, and rising healthcare expenditure. The prevalence of narcoleptic diseases is increasing, with an estimated 200,000 Americans suffering from this chronic problem. Narcolepsy disorder is often misdiagnosed due to its complex symptoms, which include daytime extreme sleepiness, sleep attacks, sleepiness, and sleep interruptions. The diagnosis involves polysomnography, a sleep study that records brain activity during sleep. Narcolepsy treatments include medications and lifestyle changes. Psychostimulants, tricyclic antidepressants, sodium oxybate, Modafinil, antiepileptics, and psychiatric medications are some of the commonly used Narcolepsy drugs.
The reimbursement environment for these drugs varies, which can impact their adoption. Central hypersomnia and circadian delay are other sleep disorders that can co-occur with Narcolepsy. Obesity rates, alcohol, and tobacco use can worsen the symptoms of Narcolepsy. The medical infrastructure for diagnosing and treating these disorders is improving, with an increasing number of hospitals and diagnostic centers offering specialized services. The development of new Narcolepsy drugs is ongoing, with a focus on improving efficacy, safety, and patient compliance. However, the addictive potential of some medications and the complex nature of the disorder pose challenges for drug development. In conclusion, the market is expected to grow due to the increasing prevalence of the disorder, improving medical infrastructure, and ongoing research and development efforts. However, the complex nature of the disorder and the challenges of developing effective and safe medications present significant opportunities and challenges for market participants.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
133 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 10.03% |
|
Market growth 2024-2028 |
USD 1.81 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
8.88 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 51% |
|
Key countries |
US, Germany, UK, Canada, and France |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Alkermes Public Ltd. Co., Apotex Inc., Aurobindo Pharma Ltd., Avadel Pharmaceuticals plc, Axsome Therapeutics Inc., BIOPROJET, Cadila Pharmaceuticals Ltd., Don Valley Pharma, Graymark Healthcare Inc., Jabs Biotech Pvt. Ltd., Jazz Pharmaceuticals Plc, Luckys Pharma Pvt. Ltd., Midas Pharma GmbH, Orbion Pharmaceuticals Pvt. Ltd., SHIONOGI Co. Ltd., Somacare, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and XWPharma Ltd. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the market forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
